Press Releases
RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics
See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutionsReal-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI... ❯❯❯
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) -- As part of Saudi Arabia’s broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom’s leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of... ❯❯❯
LifeLabs Introduces Three Blood-Based Alzheimer’s Disease Tests, Including Support Services
Toronto, Ontario, June 04, 2025 (GLOBE NEWSWIRE) -- LifeLabs, a leading provider of health diagnostics and laboratory services, is proud to announce the launch of a comprehensive portfolio of blood-based biomarker tests and support services in Ontario that assess the risk of dementia or Alzheimer’s disease. “Alzheimer’s disease presents significant challenges for Canadians, and early detection is critical for better management of... ❯❯❯
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced a research collaboration with the... ❯❯❯
Extendicare Acquires Nine Long-Term Care Homes from Revera
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare”) (TSX: EXE.TO) announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc. and certain of its affiliates to acquire nine “Class C” long-term care homes (the “Acquired Homes”) located in Ontario and Manitoba and one parcel of vacant land located in Ontario (the “Transaction”). The consideration... ❯❯❯
LifeLabs partners with POGO to support their ongoing mission of helping Ontario children with cancer
Toronto, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- LifeLabs, Canada’s leading medical laboratory, is proud to announce its continued partnership with the Pediatric Oncology Group of Ontario (POGO) to support Canadian children with cancer and their families. As part of this collaboration, LifeLabs donated $10,000, and gathered many senior leadership team members to come together and create care packages for children supported by POGO... ❯❯❯
4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population
QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate vs. 25% with conventional methodsNEWTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, unveiled groundbreaking findings at the American Society of Clinical Oncology (ASCO) 2025 Annual... ❯❯❯
Civitas Networks for Health Opens Registration for 2025 Annual Conference
Agenda and keynote details now available for the premier annual event advancing health data sharing, health improvement, and interoperabilityPORTLAND, Maine and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Civitas Networks for Health (Civitas) today announced that the agenda and registration are live for its 2025 Annual Conference, taking place September 28–30 in Anaheim, California. Hosted in partnership with 211 San Diego/CIE and... ❯❯❯
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineli... ❯❯❯
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
Pain, Misunderstood spotlights America’s outdated pain treatment with a national push for smarter MSK careLOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- What if everything we thought we knew about pain was wrong? Today, more than 1 in 5 Americans live with chronic pain, and too often, their pain is met with silence, surgery, or a prescription pad. Now, Confluent Health, a national leader in musculoskeletal (MSK) care, is shining... ❯❯❯
